Peripheral arterial disease (PAD) is associated with signi cant morbidity and mortality, and yet remains under-recognized and under-treated. Atherosclerosis is the most common cause of lower extremity PAD and pharmacological interventions that alter this central pathogenic role of atherosclerosis may alter the natural history of PAD. There is growing evidence that the renin-angiotensin system (RAS) is a signi cant mediator of this disease process and that treatment with angiotensin-converting enzyme (ACE) inhibitors is associated with vasculoprotective effects that are independent of the antihypertensive properties of these agents. Numerous lines of evidence suggest that ACE inhibitors directly inhibit the atherosclerotic process and improve vascular endothelial function. In patients with PAD, ACE inhibitors have been shown to improve peripheral circulation as measured by peripheral arterial blood pressure and by increases in peripheral blood ow. Preliminary evidence suggests that ACE inhibitors might improve clinical symptoms in patients with PAD. Recent evidence has con rmed that ACE inhibition is associated with a decrease in morbidity and mortality in patients with arterial disease without left ventricular dysfunction; this bene t was at least as great for the subset of patients with PAD. Overall, these data support a signi cant role for the RAS in the pathogenesis of all atherosclerotic diseases (including PAD) and suggest that the bene t is independent of the blood pressure lowering properties of these agents. These studies suggest that ACE inhibitor therapy should be considered in the routine management of individuals with PAD, regardless of whether they have hypertension or left ventricular dysfunction. Figure 1 A new paradigm of ACE-I use in PAD and systemic atherosclerotic syndromes. (AMI, acute myocardial infarction; CAD, coronary artery disease; CLI, critical limb ischemia; LVH, left ventricular hypertrophy; PAD, peripheral arterial disease; SCD, sudden cardiac death.) R ole of A CE in PA D 277 V ascular M edicine 2003; 8: 273-278
Introduction
Peripheral arterial disease (PAD ) is a common manifestation of the atherosclerotic disease process caused by stenoses or occlusion of the arteries to the leg. 1 The pathophysiological effect of such limb arterial stenoses is to reduce blood ow to the lower limbs both at rest and during exercise. 2 PAD affects an estimated 10-12% of the general population. 1, 3 The disease is highly prevalent throughout the world, and has been well-documented in the U SA and Europe.
Although most patients with PAD are asymptomatic, approximately one-third may experience claudication, de ned as leg muscle discomfort that is reproducibly provoked by walking, but that is consistently relieved with rest. Current data demonstrate that probably all individuals with PAD have at least some functional impairment of gait. [4] [5] [6] [7] Yet, approximately 50% are 'asymptomatic' in that they do not suffer classic claudication as de ned by standardized questionnaires. An additional 30-40% suffer atypical leg symptoms, and only 10-20% suffer classic claudication. However, all of these individuals with PAD are at increased risk of cardiovascular ischemic events and are candidates for risk reduction pharmacological interventions. Approximately 25% of patients with claudication may experience progressive symptomatic deterioration and the 5-year risk of major amputation is 1-3% . 8 The primary risk factors for the development of peripheral arterial atherosclerosis are similar to those for the coronary and cerebral vasculature and include increasing age ( > 40 years), cigarette smoking, and diabetes mellitus. 9 Hyperlipidemia and hypertension are also risk factors for PAD, although the predictive value of these parameters does not appear to be as strong as for the primary risk factors. 10 Notably, there is a signicant interaction between many of the risk factors for PAD .
Patients with PAD have a substantially increased risk of death from cardiovascular disease with the risk proportional to the severity of the disease. 11 The presence of a low ankle-brachial index (ABI) is highly predictive of both total and cardiovascular mortality, with the relative risk in cardiovascular mortality among those with a low ABI increased approximately three-to fourfold. 12, 13 D espite the well-documented morbidity and mortality among patients with PAD, the disease is often unrecognized and under-treated even when it is diagnosed. There is little awareness among most practicing physicians regarding the pathogenesis, natural history, and management of PAD until the symptoms become severe. 3, 14 It is now generally accepted that angiotensin-converting enzyme inhibitor (ACE-I) therapy is a major therapeutic opportunity that can provide cardiovascular risk reduction in patients with both complicated coronary artery disease as well as at high cardiovascular risk. 15, 16 H owever, we hypothesize that this strategy might be extrapolated to patients with PAD and thereby diminish the impact of this disease. This article will overview the pathophysiology of PAD with emphasis on the emerging role of the reninangiotensin system (RAS) as a mediator of the disease. This will be followed by a review of the experimental and clinical evidence for the use of angiotensin-converting enzyme (ACE) inhibitors in the treatment of PAD .
Pathophysiology of peripheral arterial disease
The atherosclerotic process is heralded by the arterial narrowing and occlusion that decreases blood ow to the lower limbs. 2 The most frequently observed type of lesion in PAD is a raised focal plaque that forms within the intimal layer of the arterial wall. This atherosclerotic process is considered to be a precursor to the development of clinical symptoms. However, while the anatomic pattern of atherosclerosis and decreased limb blood ow are central to clinical outcomes, these features alone cannot completely account for the manifestations of the disease since there is considerable variability in the clinical symptoms among patients with similar degrees of limb atherosclerosis.
The atherosclerotic process is induced by a complex interaction of cellular, metabolic, hemodynamic, and in ammatory processes that are poorly understood. The variable clinical manifestations of PAD appear to be related, in part, to the cellular manifestations of the disease that occur over several years and that are triggered by an initial or sustained ischemic event. These include endothelial dysfunction, microvascular capillary abnormalities, denervation, deconditioning, and mitochondrial injury to skeletal muscle. [17] [18] [19] [20] Other key factors that may determine clinical presentation include the level, severity, and diffuseness of the structural arterial lesions, as well as the presence of collateral vessels.
Role of the renin-angiotensin system (RAS)
The role of the RAS in the pathogenesis of atherosclerotic cardiovascular disease is evidenced by the clinical ef cacy of ACE inhibitors in the treatment of a wide range of cardiovascular diseases. ACE inhibitors are widely used in the treatment of hypertension, ventricular dysfunction, and severe heart failure. 21 Evidence is also emerging which supports the vascular protective role of ACE inhibitors and for their role in the management of patients at cardiovascular risk or with overt PAD.
ACE inhibitors have a number of well-described cardioprotective effects. These include improvements in cardiac hemodynamics, energetics, electrical stability, and a reduction in left ventricular mass. These properties are likely responsible for the decreased mortality among patients with left ventricular dysfunction who are treated with ACE inhibitors. [22] [23] [24] However, ACE inhibitors also have a number of vasculoprotective actions that are of relevance in the pathophysiology of PAD. In particular, the RAS has a signi cant role in the mediation of peripheral hemodynamics and in the systemic atherosclerotic process.
Angiotensin II, the primary effector molecule of the RAS, has a number of pharmacological properties. The most well known is the regulation of arterial pressure and blood volume through its direct vasoconstrictive action. Angiotensin II also facilitates the activity of both the central and the sympathetic nervous systems. 21 Angiotensin receptors are present on vascular smooth muscle cells and the vascular formation of angiotensin II occurs in proximity to vascular noradrenergic nerves. Thus, the conversion of angiotensin I to angiotensin II enhances sympathetic arterial compliance and tone. 25 In addition, angiotensin II also stimulates the secretion of aldosterone, and its effects on the myocardium and arterial wall, although these speci c effects are beyond the scope of this review.
Angiotensin II also mediates a number of nonhemodynamic processes that are relevant to the pathogenesis of PAD , such as cell-growth-induced ventricular hypertrophy and vascular remodeling. It can elicit vascular brosis, contribute to the induction of endothelial dysfunction and atherosclerosis by promoting oxidative stress, and promote atherosclerotic plaque instability. 26 The mechanisms of ACE-I mediated vascular protective effects may be related to decreased proliferation and migration of smooth muscle cells, anti-in ammatory effects, decreased oxidative stress, protection from plaque rupture, antiplatelet effects, and enhancement of endogenous brinolysis. 27, 28 These bene ts appear to be mediated not only through the inhibition of angiotensin II but also through its potentiating effect on bradykinin. This is because ACE is identical to kinase II, an enzyme that degrades bradykinin. Bradykinin is a potent vasodilator that acts through a stimulation of the release of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor. 29, 30 Nitric oxide has a number of potentially bene cial effects, such as the inhibition of platelet adhesion and aggregation and smooth muscle cell mitogenesis and proliferation.
Effect of ACE inhibition on atherosclerosis and endothelial function
Studies in several animal models of atherosclerosis have demonstrated that ACE inhibitors decrease the genesis of atherosclerotic lesions through antiproliferative and antimigratory effects. 31, 32 Studies using animal models of accelerated atherosclerosis have demonstrated that ACE inhibition decreases the accumulation of macrophages into the neointima of the artery wall. 33 Since these cells are involved in the development of atherosclerotic lesions, decreasing their migration may prevent lesion formation.
ACE inhibitors have been shown to improve or restore endothelial function in animal studies 34, 35 as well as in patients with coronary artery disease. 36, 37 In the TR EN D study, quinapril was shown to attenuate impaired endothelial vasomotor function in normotensive patients with coronary artery disease, preserved left ventricular function, and minimal or mild dyslipidemia. 38 These data suggest that the bene cial effects of ACE inhibitors on endothelial function are independent of their blood pressure lowering effects. The mechanism is likely related to ACE-I-mediated increases in bradykinin and nitric oxide which have a number of potentially vasculoprotective actions.
ACE inhibition in PAD
Experimental models (Table 1) Several studies in animal models of PAD have demonstrated that ACE inhibitors can play a signi cant role in modulating the disease. In a rabbit of hindlimb ischemia, ACE inhibition with quinaprilat, but not with captopril, promoted angiogenesis. 39 The improvement was evident for 5 days after the discontinuation of quinaprilat, indicating that the effect re ected a modi cation of the hindlimb vasculature rather than a simple transient improvement in endothelium-dependent blood ow. The differing effects between ACE inhibitors also suggest that those agents with higher tissue ACE activity (i.e. quinaprilat) may be more effective for angiogenesis in ischemic tissue. Another study in spontaneously hypertensive rats found that captopril administration was associated with the prevention of peripheral ischemia-induced capillary growth. 40 Overall, these data suggest that the R AS may play an important role in the adaptive mechanisms in response to skeletal muscle ischemia.
Clinical studies (Table 1)
A number of studies have been conducted to evaluate the effect of ACE inhibitors in patients with PAD with or without concomitant hypertension. These studies evaluated the effect of ACE-I on limb blood ow, walking distance, ABI progression to critical limb ischemia, and cardiovascular morbidity and mortality. The majority of these investigations included patients with intermittent claudication and hypertension.
L imb blood ow
Resting limb blood ow increases in patients with PAD in response to ACE-I administration. In a randomized, double-blind trial, Sonecha et al 41 demonstrated that treatment with enalapril was associated with a signi cant increase in resting blood ow and a decrease in peripheral resistance compared with patients who received placebo.
Similarly, treatment with captopril produced a signi cantly greater increase in blood ow velocity at rest, after exercise, and after recovery compared with placebotreated patients. 42 In randomized, crossover trials in patients with PAD, ACE inhibitors have been shown to produce signi cantly greater improvements in peripheral blood ow compared with either calcium channel blockers or beta blockers. 43, 44 Overall, these data suggest that treatment with ACE inhibitors produces hemodynamic improvements in the extremity in which baseline blood ow is decreased by limb arterial atherosclerosis. The results are similar to those obtained in patients with heart failure, where ACE inhibitors have been shown to improve peripheral blood ow and exercise tolerance. 45 These results remain controversial, as such data have not been consistently reproduced. 46 
W alking distance and claudication
Other studies have examined the effect of ACE inhibitors on clinical symptoms among patients with PAD . Bernardi et al 42 demonstrated that captopril was associated with a more prolonged onset of lower extremity discomfort after exercise than either placebo or nicardipine. Several studies have also shown that treatment with ACE inhibitors is associated with improvements in pain-free walking distance and total walking distance. 44, [46] [47] [48] The effect on pain-free walking distance was signi cantly greater than that produced by beta-blockers 44 in comparative trials. There was no difference in these clinical effects between ACE-I and calcium antagonists. Although these limited evaluations have been positive, no well-powered clinical investigation of ACE-I impact on claudication symptoms has yet been performed.
A nk le-brachial index
Data from randomized controlled trials have demonstrated that ACE-I therapy is associated with the maintenance of peripheral circulation among patients with PAD as evidenced by signi cant improvements in either the ankle systolic pressure or ABI. 47, 48 N o prospective, wellpowered clinical trials have yet evaluated whether multiyear ACE-I use can either improve or blunt the deterioration in the ABI.
Progression to critical limb ischemia ( CL I)
To date, there are no data available that have examined the effect of ACE-I in PAD patients to demonstrate inhibition of rates of progression to CLI in this particular patient group.
Cardiovascular morbidity and mortality
Overall, the results indicate that ACE inhibitors have a number of potentially bene cial effects in these patients. ACE inhibitors have a well-established effect in reducing mortality and symptoms of heart failure in patients with left-ventricular dysfunction, as well as in patients with post-myocardial infarction. [22] [23] [24] 49 More recently, two trials have evaluated the effect of ACE inhibitors on cardiovascular outcomes in patients with vascular disease but without evidence of left ventricular dysfunction (ejection fraction 40% ). 15, 50 In the Heart Outcomes Prevention Evaluation (HOPE) study, 9541 patients with evidence of arterial disease or diabetes plus one other cardiovascular risk factor were randomly assigned to ramipril 10 mg=day or placebo for a mean of 5 years. 15 Patients were required to be at least 55 years of age and to have a history of coronary artery disease, stroke, PAD , or diabetes plus at least one other risk factor (hypertension, hyperlipidemia, cigarette smoking, or microalbuminuria). Patients with PAD represented a large fraction 4051=9297 (44% ) of the total study population. Among the overall HOPE study population, the primary outcome parameter (composite of myocardial infarction, stroke, or death from cardiovascular causes during placebo treatment) was more frequent in the PAD cohort (22.0% ) versus the non-PAD cohort (14.3% ), re ecting the high relative risk of ischemic events in individuals with PAD. D uring treatment with ramipril, there was a large risk reduction in individuals with PAD compared with the non-PAD subjects. While the most stringent interpretation of the H OPE study suggests that ramipril offers a consistent bene t across all pre hoc de ned subgroups, the post-hoc analysis demonstrates a magni ed relative risk reduction (R RR) in individuals with PAD . F or other subgroups in which placebotreatment ischemic event rates were comparably high (e.g. individuals with hypertension, prior myocardial infarction, or cerebrovascular disease), such a magni ed RRR was not consistently observed. Ramipril was also associated with signi cant reductions in each of the critical clinical endpoints when they were evaluated individually: cardiovascular death (26% R RR, p < 0.001), myocardial infarction (20% RR R, p < 0.001), or stroke (32% R RR, p < 0.001). Patients receiving ramipril also underwent signi cantly fewer cardiac or peripheral arterial revascularization procedures (16.0% vs 18.3% , 15% R RR, pˆ0.002). In addition, there were signi cantly fewer ramipril-than placebo-treated patients who suffered cardiac arrest, worsening angina, heart failure, or who received a new diagnosis of diabetes or complications related to diabetes. In the speci c subgroup of PAD patients in the HOPE study, this particular subgroup gained even more bene t from ramipril compared with those who did not have PAD . In fact, the RRR was 22% in the PAD group, but only 14.7% in the non-PAD group for the composite outcome. In addition, bene ts were observed whether or not these patients were also taking aspirin or other antiplatelet agents, betablockers, lipid-lowering agents, or antihypertensive drugs at randomization, suggesting that the bene ts of ACE inhibition are additive to that of other agents.
We note that other subgroups of patients in the HOPE study who had signi cant reductions in the combined endpoint included both those with or without hypertension, suggesting that only a small portion of the bene t could be related to a blood pressure lowering effect. However, Svensson et al 51 compared the effects of ramipril on ambulatory and of ce blood pressures in a subgroup of PAD patients in the H OPE study. After 1 year, night and 24-h ambulatory blood pressure decreased signicantly, while there was no signi cant decrease in the of ce and day ambulatory blood pressure. As patients with PAD often experience isolated systolic hypertension, the expected cardiovascular risk reduction bene t should be especially prominent.
In the MICR O-H OPE study, which included 3654 patients from the H OPE study who had diabetes, ramipril lowered the combined primary outcome by 25% . 52 The effect was independent of whether the patients had a history of cardiovascular disease, hypertension, or microabluminuria, suggesting that the drug has a vasculoprotective effect on the arterial wall.
In addition to cardiovascular event reduction, ACE-I use has been shown to diminish the progression of non-coronary atherosclerosis. In the Study to Evaluate Carotid U ltrasound Changes in Patients Treated with Ramipril and Vitamin E (SECU RE), a substudy of the HOPE study, treatment with ramipril was associated with a signi cant reduction in the rate of atherosclerosis progression. The progression slope of the mean maximum carotid intimal media thickness was 0.0217 mm=year in the placebo group, 0.0180 mm=year in the ramipril 2.5 mg=day and 0.0137 mm=year in the ramipril 10 mg=day group. 36 The effect was independent of the blood pressure lowering effect of ramipril, again supporting a direct vasculoprotective effect. It is notable, however, that the benecial effect noted in SECU RE was in contrast to other studies evaluating the effect of ACE inhibitors on atherosclerosis progression, especially in the coronary circulation, in which no signi cant effect was demonstrated. 50, 53, 54 Differences in the results of these trials may be related to the methods used for the assessment of atherosclerosis, distinct effects on atherosclerosis in coronary versus cerebral arterial beds, patient populations, study design, and the type and dose of ACE-I used.
R ecently, the PR OGRESS study 55 revealed that perindopril or the combination of perindopril with indapamide in patients who had suffered a stroke reduced the risk of stroke among both hypertensive and nonhypertensive individuals by 26% and 43% , respectively. Moreover, the relative risk for major coronary events was reduced signi cantly by 26% .
The EU ROPA study will give us even more insight about the role of ACE-I in patients with stable coronary artery disease with no evidence of heart failure. Additional information will be obtained from a limited number of patients with PAD (7% ) in this trial. The results of this trial have been published very recently, and showed that the ACE-I perindopril among patients with stable coronary heart disease without heart failure signi cantly improves outcomes. 56
Conclusions
While the etiology of PAD is complex, the RAS appears to serve a detrimental role in the progression of this lower limb manifestation of systemic atherosclerosis. ACE inhibitors have been shown to retard atherosclerosis and to improve endothelial dysfunction in patients with a broad range of atherosclerotic diseases, including those with PAD, with bene cial clinical effects (F igure 1). Although the mechanisms underlying these bene cial effects of ACE inhibitors on PAD are not fully known, they do appear to be related to properties other than blood pressure lowering. Numerous studies have demonstrated that ACE inhibitors are effective in maintaining the peripheral circulation in patients with PAD and preliminary data suggest that ACE-I use can be associated with improvements in clinical parameters. Use of ACE-I has been proven to offer bene cial risk reduction in cardiovascular and cerebrovascular outcomes beyond those achieved by other secondary preventive strategies commonly applied for patients with vascular disease. Of all cardiovascular disease risk cohorts, patients with PAD are at the highest risk for a cardiovascular event.
Thus, in this large, high-risk population, wiser use of ACE-I should be strongly considered. The pathophysiologic role of the RAS and of ACE-I bene t in individuals with PAD will undoubtedly be increasingly explored and their impact de ned by future clinical trials.
